0001827506-24-000076.txt : 20240822 0001827506-24-000076.hdr.sgml : 20240822 20240822162214 ACCESSION NUMBER: 0001827506-24-000076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240821 FILED AS OF DATE: 20240822 DATE AS OF CHANGE: 20240822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kulkarni Sandeep Chidambar CENTRAL INDEX KEY: 0001945691 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 241232257 MAIL ADDRESS: STREET 1: 92 MORNINGSIDE AVE. STREET 2: APT 7E CITY: NEW YORK STATE: NM ZIP: 10027 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tourmaline Bio, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-481-9832 MAIL ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Talaris Therapeutics, Inc. DATE OF NAME CHANGE: 20201007 4 1 wk-form4_1724358128.xml FORM 4 X0508 4 2024-08-21 0 0001827506 Tourmaline Bio, Inc. TRML 0001945691 Kulkarni Sandeep Chidambar C/O TOURMALINE BIO, INC. 27 WEST 24TH STREET, SUITE 702 NEW YORK NY 10010 1 1 0 0 CEO 0 Common Stock 2024-08-21 4 P 0 1779 14.85 A 7000 I By Gilead Capital, LP The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.82 to $14.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose. /s/ Brad Middlekauff, Attorney-in-Fact 2024-08-22